Catecholamine-induced cardiotoxicity: A critical element in the pathophysiology of stroke-induced heart injury

Yuxin Du1, Laurie J Demillard2, Jun Ren3

  • 1Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai 200032, China.

Life Sciences
|November 10, 2021
PubMed

Insights

Cerebrovascular diseases trigger heart issues via catecholamine surges. This review details how norepinephrine and epinephrine cause cardiotoxicity through mechanisms like calcium overload and oxidative stress.

Area of Science:

  • Neuroscience
  • Cardiology
  • Pathophysiology

Background:

  • Cerebrovascular diseases (stroke, hemorrhage) induce cardiac complications like heart failure and cardiomyopathy.
  • Pathways include gut dysbiosis, inflammation, microvesicle/microRNA injury, and catecholamine surges.

Purpose of the Study:

  • To review molecular mechanisms of catecholamine-induced cardiotoxicity following cerebrovascular events.
  • To elucidate the role of norepinephrine and epinephrine in cardiac damage.

Main Methods:

  • Literature review of studies on cerebrovascular disease and cardiac complications.
  • Analysis of molecular pathways involved in catecholamine-mediated cardiotoxicity.

Main Results:

  • Cerebrovascular diseases provoke catecholamine surges via multiple pathways.
  • Catecholamines (norepinephrine, epinephrine) induce myocardial ischemia, Ca2+ overload, oxidative stress, and mitochondrial dysfunction.

Conclusions:

  • Catecholamine surges are a key mechanism linking brain injury to heart damage.
  • Understanding these pathways is crucial for managing cardiac complications of cerebrovascular diseases.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
567
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
100
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
881
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
822
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.7K